Global Cancer (Tumor) Profiling Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Cancer (Tumor) Profiling Market Research Report 2024
Cancer(tumor) profiling is the technology oncologists use to determine if the pathways of a patient's tumor match up with available targeted treatments. Tumor profiling starts with obtaining a sample of tumor tissue. The tissue is usually collected through a core biopsy, but it can also be taken during surgery.
According to MRAResearch’s new survey, global Cancer (Tumor) Profiling market is projected to reach US$ 19410 million in 2033, increasing from US$ 9265 million in 2022, with the CAGR of 11.2% during the period of 2023 to 2033.
Surging cancer prevalence across the globe is one of the major factors contributing to the market growth. Cancer is the second leading cause of death worldwide. One in six deaths worldwide is due to cancer. In middle- and lower-class economies, 70% of deaths are due to cancer. This expands the growth scope of the market. Surging public-private funding of targeted research activities, emergence of cancer profiling relative to traditional methods of cancer diagnosis, increasing geriatric population base, and increasing product innovation and development due to technological advancements across the world will provide lucrative opportunities for market players. Estimated period 2022-2033. In addition, the surge in the number of strategic cooperations, rising Internet penetration, increasing number of hospitals and laboratories, increasing cases of lung cancer, prostate cancer, and acute leukemia, and increasing healthcare expenditure per capita will lead to further expansion of the market growth rate in the future.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cancer (Tumor) Profiling market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Illumina
Qiagen
Neogenomics Laboratories
HTG Molecular Diagnostics
Genomic Health
Caris Life Sciences
Helomics Corporation
Nanostring Technologies
Oxford Gene Technology
Ribomed Biotechnologies
Segment by Type
Immunoassay
NGS
Mass Spectrometry
Others
Clinical
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cancer (Tumor) Profiling report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Cancer (Tumor) Profiling market is projected to reach US$ 19410 million in 2033, increasing from US$ 9265 million in 2022, with the CAGR of 11.2% during the period of 2023 to 2033.
Surging cancer prevalence across the globe is one of the major factors contributing to the market growth. Cancer is the second leading cause of death worldwide. One in six deaths worldwide is due to cancer. In middle- and lower-class economies, 70% of deaths are due to cancer. This expands the growth scope of the market. Surging public-private funding of targeted research activities, emergence of cancer profiling relative to traditional methods of cancer diagnosis, increasing geriatric population base, and increasing product innovation and development due to technological advancements across the world will provide lucrative opportunities for market players. Estimated period 2022-2033. In addition, the surge in the number of strategic cooperations, rising Internet penetration, increasing number of hospitals and laboratories, increasing cases of lung cancer, prostate cancer, and acute leukemia, and increasing healthcare expenditure per capita will lead to further expansion of the market growth rate in the future.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Cancer (Tumor) Profiling market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Illumina
Qiagen
Neogenomics Laboratories
HTG Molecular Diagnostics
Genomic Health
Caris Life Sciences
Helomics Corporation
Nanostring Technologies
Oxford Gene Technology
Ribomed Biotechnologies
Segment by Type
Immunoassay
NGS
Mass Spectrometry
Others
Segment by Application
Clinical
Research
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Cancer (Tumor) Profiling report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices